by Portfolio Grader | April 5, 2013 8:00 am
The ratings of three Pharmaceutical stocks are down this week, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
VIVUS Inc.’s (NASDAQ:VVUS) rating falls to a D (“sell”) this week, down from C (“hold”) the week prior. VIVUS is a biopharmaceutical company engaged in the development and commercialization of therapeutic products for large underserved markets. VVUS also rates an F in Portfolio Grader’s specific subcategory of Equity. The stock price has fallen 7.4% over the past month, worse than the Nasdaq, which has held flat over the same period of time. As of April 5, 2013, 23.9% of outstanding VIVUS Inc. shares were held short. For more information, get Portfolio Grader’s complete analysis of VVUS stock.
Cempra Holdings LLC’s (NASDAQ:CEMP) rating weakens this week, dropping to a D versus last week’s C. Cempra, Inc. manufactures and markets pharmaceutical products. It is a clinical-stage pharmaceutical company, which focuses on developing antibiotics to meet critical unmet medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and skin and skin st… The stock gets F’s in Equity and Cash Flow. Investors seem to agree with the downgrade and have pushed down the share price 5.3% over the past month. For a full analysis of CEMP stock, visit Portfolio Grader.
Corcept Therapeutics (NASDAQ:CORT) ratings are on the decline this week as the company earns an F (“strong sell”). Last week, it received a D (“sell”). Corcept Therapeutics engages in the discovery, development, and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders. The stock gets F’s in Equity and Cash Flow. To get an in-depth look at CORT, get Portfolio Grader’s complete analysis of CORT stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
Source URL: http://investorplace.com/2013/04/3-pharmaceutical-stocks-to-sell-now-vvus-cemp-cort/
Short URL: http://invstplc.com/1fvPKqz
Copyright ©2017 InvestorPlace Media, LLC. All rights reserved. 700 Indian Springs Drive, Lancaster, PA 17601.